Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -19.66% | -31.29% | 4.33% | -- |
| Gross Profit | -- | 19.66% | 31.29% | -4.33% | -- |
| SG&A Expenses | 71.84% | 13.22% | 22.63% | -13.65% | 40.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.93% | -12.74% | -4.29% | -0.11% | 32.82% |
| Operating Income | 10.93% | 12.74% | 4.29% | 0.11% | -32.82% |
| Income Before Tax | 8.94% | 10.99% | -0.84% | -6.65% | -46.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.94% | 10.99% | -0.84% | -6.65% | -46.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.94% | 10.99% | -0.84% | -6.65% | -46.10% |
| EBIT | 10.93% | 12.74% | 4.29% | 0.11% | -32.82% |
| EBITDA | 10.87% | 12.56% | -90.72% | -0.15% | -31.50% |
| EPS Basic | 35.37% | 36.35% | 7.55% | -6.02% | -45.76% |
| Normalized Basic EPS | 35.37% | 36.34% | 7.55% | -6.03% | -45.78% |
| EPS Diluted | 35.37% | 36.35% | 7.55% | -6.02% | -45.76% |
| Normalized Diluted EPS | 35.37% | 36.34% | 7.55% | -6.03% | -45.78% |
| Average Basic Shares Outstanding | 40.88% | 39.84% | 9.08% | 0.60% | 0.23% |
| Average Diluted Shares Outstanding | 40.88% | 39.84% | 9.08% | 0.60% | 0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |